IP Verse

Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases

Patent No. EP3227333 (titled "Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases") was filed by Bristol Myers Squibb on Dec 2, 2015. The application was issued on Aug 16, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
PFIZERMay 16, 2024PFIZER
SCORPIOMay 16, 2024SAGITTARIUS
J A KEMPMay 14, 2024J A KEMP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3227333

BRISTOL MYERS SQUIBB
Application Number
EP15804458A
Filing Date
Dec 2, 2015
Status
Revoked
Aug 22, 2025
Publication Date
Aug 16, 2023
External Links
Slate, Register , Google Patents